FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and pharmacy. Disclosed is use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or a salt thereof for the treatment of secondary hyperparathyroidism or symptoms thereof in a human subject, having secondary hyperparathyroidism in addition to renal failure, without inducing hypercalcemia in a human subject, where 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 is formulated in a dose for oral or parenteral administration from 40 ng/day to 600 ng/day to a subject; the corresponding composition of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 of the same purpose and method of treatment. Technical result is that the invention provides a reduction in parathyroid hormone (PTH) levels in the patient's serum; wherein said effect is long-lasting against the zemplar comparison preparation.
EFFECT: invention provides maintenance of calcium levels in women after menopause within a physiologically normal range.
9 cl, 13 dwg, 4 ex
